

Table of Contents

1	Introduction	7
1.1	Foundation for the Good Practice Guide	8
1.2	Global Acceptance/Authorization	9
1.3	Scope.....	12
1.4	Purpose.....	12
1.5	Benefits	13
2	Basic Terms Used in the Process Validation Lifecycle.....	15
2.1	Process Validation Lifecycle Stages	15
2.2	Stage 1 Process Design/Pharmaceutical Development	16
2.3	Stage 2 Key Terms and Substages.....	17
2.4	Stage 3 Continued (Ongoing) Process Verification and Substages.....	18
2.5	Key Statistical Terms.....	19
3	Design Development Phase (Stage 1).....	21
3.1	Apply Statistics in PV Stage 1.....	22
3.2	Assess Variability in Stage 1	24
3.3	Leverage Stage 1 Data	28
3.4	Determine Design Space and Control Strategy.....	31
3.5	Validation Master Plan	44
3.6	Readiness for Stage 2 (Process Performance Qualification).....	45
4	Design and Qualification of Facility, Utilities, and Equipment (Stage 2.1)	49
4.1	Overview and Background.....	49
4.2	Review of Establishing Equipment Qualification Ranges	50
4.3	Impact of Product and Process on Facilities, Utilities, and Systems	50
5	Initial Process Qualification Activities (Stage 2.2)	53
5.1	Determine an Appropriate Number of Initial Process Validation Batches and Inter-Batch Variability Assessment.....	53
5.2	Determine Science and Statistically-Based Process Validation Acceptance Criteria and Sampling Plans ...	58
5.3	Process Validation (Process Performance Qualification) Acceptance Criteria	67
5.4	Stage 2.2 Process Review.....	73
6	Continued Process Verification (Stage 3)	77
6.1	Determine the Continued Process Verification Plan	77
6.2	Determine which Variability to Include in the Continued Process Verification Plan	79
6.3	Determining Statistically-based Routine Sampling and Testing for Continued Process Verification.....	82
6.4	Dissolution	91
6.5	Evaluate Legacy Products for Heightened Monitoring/Testing Need.....	93
6.6	Periodic Review and Revalidation	95
6.7	Report: Frequency, Recommendations for Further Actions, Relevance with Annual Product Review	97
7	Contract Manufacturing	99
7.1	Contract Development, Manufacturing, and Packaging Organizations and License Holder Relationship....	99
7.2	Maintaining Compliance while Ensuring Flexibility	99
7.3	Best Practices in Stage 1.....	99
7.4	Best Practices in Stage 2.....	101
7.5	Best Practices in Stage 3.....	102
7.6	Stage Gate Processes.....	102
7.7	Regulatory Audit Expectations.....	105
7.8	Contract Development, Manufacturing, and Packaging Organizations – Specialized versus One Source Models.....	105

8	Change Management	107
8.1	Change Management Principles.....	107
8.2	Changing Manufacturing Sites.....	109
9	Appendix 1 – Case Study: Legacy Products	111
9.1	Executive Summary.....	111
9.2	Case Study Overview and Background.....	111
9.3	Critical Quality Attributes Operating Characteristic Curves.....	114
9.4	Estimate the Number of Samples for the Process Validation Stage 2.2 Protocol.....	118
9.5	Assess Stage 2.2 Data.....	119
9.6	Product Risk Evaluation and Enhanced Controlled Strategy for Continued Process Verification (Stage 3.1).....	122
10	Appendix 2 – NDA Products Case Studies: Small Molecules	125
10.1	Case Study 1: Selection of CQAs and PPs for CPV – Applying Risk-based Approach to CPV Determination to a New Small Molecule Drug Product, Utilizing Data from the <i>ISPE PQLI® Guide Part 2 – Illustrative Example</i> [35].....	125
10.2	Case Study 2: Batch Size Reduction Process Performance Qualification.....	132
11	Appendix 3 – NDA Products Case Studies: Large Molecules or Bio-derived Products	143
11.1	Case Study 1: Large Molecule Example Column Chromatography Step – Parameter Selection for CPV [35].....	143
11.2	Case Study 2: Process Validation of a Cell Culture Product.....	149
12	Appendix 4 – Contract Manufacturing Product Case Studies	159
12.1	Case Study 1: Insufficient Information Transfer in Design.....	159
12.2	Case Study 2: Allowing Flexibility.....	160
13	Appendix 5 – Additional Information on Determining the Number of Process Performance Qualification Batches	161
13.1	Further Explanation of Risk Assessment in Preparation for Determining the Number of PPQ Batches [34].....	161
13.2	Determining the Number of PPQ Batches Based on a Risk-based Approach Utilizing the <i>ISPE PQLI® Guide Part 2 – Illustrative Example</i> [8] [34].....	165
14	Appendix 6 – Statistical Detail	173
14.1	Operating Characteristic Curves of Sampling Plans and Acceptance Criteria.....	173
14.2	k Value Approximation for Two-Sided Tolerance Interval.....	175
14.3	Generation of Acceptance Limit Table for Two-Sided Tolerance Interval Approach.....	175
14.4	OC Curves for USP UDU <905> Test [46] Based on 85% – 115% Coverage.....	176
14.5	“Exact” Method – Statistical Details.....	176
14.6	R Program to Generate Acceptance Limit Tables for the Exact Method.....	179
14.7	Approximation to Exact Acceptance Limits Using a Polygon.....	180
14.8	Graphical Comparison of Acceptance Limit Tables.....	182
14.9	Operating Characteristic Curves to Help Select Sampling Plan.....	183
14.10	Formula for Calculating the Tolerance Interval Endpoints [54].....	185
14.11	Dissolution Acceptance Limit Tables.....	186
15	Appendix 7 – References	191
16	Appendix 8 – Glossary	195
16.1	Acronyms and Abbreviations.....	195
16.2	Definitions.....	199